不确定意义的KCNC2变体也与各种形式的有关
Simone Seiffert1,2, Manuela Pendziwiat3,4, Ulrike B S Hedrich2
1Department of Human Genetics, University Hospital Ulm, Ulm, Germany.
Frontiers in neurology
|June 26, 2023
概括
新的KCNC2基因变异可能导致. 功能性研究表明,这些变异改变了通道K_V3.2的功能,这表明KCNC2在病原发生过程中发挥了更广泛的作用.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
背景情况:
- 编码通道亚单元K_V3.2的KCNC2的生殖基因突变与遗传通用 (GGE) 和发育性和性脑病变 (DEE) 等综合征有关.
- 许多已识别的KCNC2变体的确切功能影响尚不清楚,需要进一步调查.
研究的目的:
- 在功能上描述三个不确定的KCNC2变异和一个致病变异.
- 在KCNC2相关的背景下,探索酸 (VPA) 对K_V3.2通道功能的潜在治疗作用.
主要方法:
- 使用Xenopus laevis卵细胞进行了电生理学研究,以评估KCNC2变体的功能.
- 使用全细胞补丁记录来测量离子通道活性.
主要成果:
- 不确定意义的KCNC2变体显示了变化的电流幅度和激活/停机动力学,这表明它们可能会导致.
- 在本研究中,瓦尔酸没有改变K_V3.2通道的电生理特性.
- 用酸治疗的患者观察到的发作减少可能是由独立于直接K_V3.2通道调节的机制调节的.
结论:
- KCNC2变异,即使最初具有不确定的意义,也可能表现出功能性改变,与的作用一致.
- 酸在KCNC2相关的治疗疗效可能涉及K_V3.2通道的直接调节以外的途径.
更多相关视频
相关概念视频
Seizures: Classification
439
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
439
Epilepsy and Seizures: Overview
228
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
228
Antiepileptic Drugs: Potassium Channel Activators
217
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
217
Antiepileptic Drugs: Calcium Channel Blockers
472
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
472
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
351
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
351
Antiepileptic Drugs: Sodium Channel Blockers
690
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
690


